VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
44 hedge funds and large institutions have $19.6M invested in Viracta Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
54% less capital invested
Capital invested by funds: $42.5M → $19.6M (-$22.9M)
Holders
44
Holding in Top 10
3
Calls
$47K
Puts
$10K
Top Buyers
| 1 | +$942K | |
| 2 | +$786K | |
| 3 | +$360K | |
| 4 |
BlackRock
New York
|
+$131K |
| 5 |
Two Sigma Investments
New York
|
+$120K |
Top Sellers
| 1 | -$5M | |
| 2 | -$2.16M | |
| 3 | -$816K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$663K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$288K |